866-997-4948(US-Canada Toll Free)

PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

Published By :

GlobalData

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : N/A

PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

Summary

Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).

The pharmaceutical industrys battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.

Scope

- Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Executive Summary 13
2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period 14
2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments 17
2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges 18
2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace 19
2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace 20
2.6 What Do Physicians Think? 22
3 Introduction 26
3.1 Catalyst 26
3.2 Related Reports 27
3.3 Upcoming Related Reports 27
4 Disease Overview 28
4.1 Infection Scope and Coverage Overview 28
4.2 Etiology and Pathophysiology 28
4.2.1 Etiology 28
4.2.2 Pathophysiology 37
4.3 Symptoms 48
4.4 Prognosis 49
5 Epidemiology 51
5.1 Disease Background 51
5.2 Risk Factors and Comorbidities 52
5.3 Global and Historical Trends 53
5.3.1 US 53
5.3.2 5EU 54
5.3.3 Japan 54
5.4 Forecast Methodology 55
5.4.1 Sources 56
5.4.2 Forecast Assumptions and Methods 59
5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016-2026) 68
5.5.1 Suspected Incident Cases of Select HAIs 68
5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs 69
5.5.3 Suspected Incident Cases of Select HAIs by Infection Site 70
5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site 71
5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent 72
5.6 Discussion 76
5.6.1 Epidemiological Forecast Insight 76
5.6.2 Limitations of the Analysis 78
5.6.3 Strengths of the Analysis 78
6 Disease Management 80
6.1 Diagnosis and Treatment Overview 80
6.1.1 Diagnosis 80
6.1.2 Treatment Guidelines 82
6.1.3 Clinical Practice 84
6.1.4 Antibiotic Stewardship Programs 85
6.1.5 Off-Label Use of Antibiotics 87
6.2 US. 87
6.3 5EU. 90
6.4 Japan. 92
7 Competitive Assessment 94
7.1 Overview 94
7.2 Product Profiles - Beta-Lactam Antibiotics 100
7.2.1 Overview 100
7.2.2 Fixed Dose Beta-Lactam Combination Drugs 101
7.2.3 Monobactam antibiotics 119
7.2.4 Carbapenems 122
7.2.5 Cephalosporins 133
7.3 Product Profiles - Fluoroquinolones 135
7.3.1 Overview 135
7.3.2 Levofloxacin (numerous brand names) 137
7.3.3 Ciprofloxacin (numerous brand names) 140
7.3.4 Moxifloxacin (numerous brand names) 143
7.4 Product Profiles - Polymixins 145
7.4.1 Overview 145
7.4.2 Forecast 147
7.5 Product Profiles - Aminoglycosides 147
7.5.1 Overview 147
7.5.2 Amikacin (numerous brand names) 150
7.5.3 Gentamicin (numerous brand names) 153
7.5.4 Tobramycin (numerous brand names) 156
7.6 Product Profiles - Tetracyclines 157
7.6.1 Tygacil (tigecycline) 157
7.7 Product Profiles - Other Antibiotics 161
8 Unmet Needs Assessment and Opportunity Analysis 163
8.1 Overview 163
8.2 Novel Approaches in Drug Development to Address Antibiotic Resistance 165
8.2.1 Unmet Need 165
8.2.2 Gap Analysis 166
8.2.3 Opportunity 166
8.3 Novel Broad-Spectrum Antibiotics 167
8.3.1 Unmet Need 167
8.3.2 Gap Analysis 168
8.3.3 Opportunity 168
8.4 Antibiotics Positioned as Pathogen- and Resistance-Specific Therapies 169
8.4.1 Unmet Need 169
8.4.2 Gap Analysis 170
8.4.3 Opportunity 170
8.5 Expansion of Antimicrobial Stewardship Programs and Awareness 171
8.5.1 Unmet Need 171
8.5.2 Gap Analysis 172
8.5.3 Opportunity 173
8.6 Financial Incentives for Drug Development and Collaborative Efforts Between Governments/Non-Profits/For-Profits 174
8.6.1 Unmet Need 174
8.6.2 Gap Analysis 175
8.6.3 Opportunity 176
8.7 Improved Diagnostics for Pathogens and Resistance Patterns 177
8.7.1 Unmet Need 177
8.7.2 Gap Analysis 177
8.7.3 Opportunity 178
8.8 Improving the Safety and Administration Profile of Antibiotics 179
8.8.1 Unmet Need 179
8.8.2 Gap Analysis 180
8.8.3 Opportunity 181
8.9 Improved Clinical Trial Design 181
8.9.1 Unmet Need 181
8.9.2 Gap Analysis 182
8.9.3 Opportunity 182
8.10 Improved Prevention of Healthcare-Associated Infections 183
8.10.1 Unmet Need 183
8.10.2 Gap Analysis 183
8.10.3 Opportunity 183
9 Pipeline Assessment 185
9.1 Overview 185
9.2 Promising Drugs in Clinical Development 187
9.2.1 Antibiotics 190
9.2.2 Antibodies 231
9.3 Other Drugs in Development 241
10 Current and Future Players 243
10.1 Overview 243
10.2 Trends in Corporate Strategy 245
10.3 Company Profiles - Current Players 247
10.3.1 Pfizer 247
10.3.2 Merck& Co. 248
10.3.3 The Medicines Company 249
10.3.4 Shionogi & Co., Ltd. 251
10.3.5 Tetraphase Pharmaceuticals Inc. 252
10.3.6 MerLion Pharmaceuticals Pte., Ltd. 253
10.3.7 Achaogen 254
10.3.8 Aridis Pharmaceuticals 255
10.3.9 MedImmune LLC 257
10.3.10 Allergan 258
10.4 Other Companies With Early-Stage Products 259
10.4.1 Roche/Genentech 259
10.4.2 Wockhardt Ltd. 260
10.4.3 Allecra 260
10.4.4 Zavante 261
11 Market Outlook 262
11.1 Global Markets 262
11.1.1 Forecast 262
11.1.2 Drivers and Barriers - Global Issues 267
11.2 US.. 267
11.2.1 Forecast 267
11.2.2 Key Events 272
11.2.3 Drivers and Barriers 273
11.3 5EU. 273
11.3.1 Forecast 273
11.3.2 Key Events 278
11.3.3 Drivers and Barriers 279
11.4 Japan 279
11.4.1 Forecast 279
11.4.2 Key Events 284
11.4.3 Drivers and Barriers 285
12 Appendix 286
12.1 Bibliography 286
12.2 Abbreviations 332
12.3 Methodology 337
12.3.1 Forecasting Methodology 337
12.3.2 Suspected Infections and Diagnosed Patients 337
12.3.3 Percent Drug-Treated Patients 338
12.3.4 Antibiotic Resistance Patterns 339
12.3.5 Drugs Included in Each Therapeutic Class 340
12.3.6 Launch and Patent Expiry Dates 340
12.3.7 General Pricing Assumptions 343
12.3.8 Individual Drug Assumptions 344
12.3.9 Generic Erosion 366
12.3.10 Pricing of Pipeline Agents 366
12.4 Primary Research - Key Opinion Leaders Interviewed for This Report 370
12.5 Primary Research - Prescriber Survey 373
12.6 About the Authors 374
12.6.1 Analyst 374
12.6.2 Therapy Area Director 374
12.6.3 Epidemiologist 375
12.6.4 Reviewers 375
12.6.5 Global Director of Therapy Analysis and Epidemiology 376
12.6.6 Global Head and EVP of Healthcare Operations and Strategy 377
12.7 About GlobalData 378
12.8 Contact Us 378
12.9 Disclaimer 379

1.1 List of Tables
Table 1: Healthcare-Associated Infections by Gram-Negative Bacteria: Key Metrics in the Seven Major Pharmaceutical Markets 13
Table 2: Characteristics of Most Important Gram-Negative Bacteria 31
Table 3: Prevalence of Antibiotic Resistance in Gram-Negative Bacteria Throughout the 7MM 42
Table 4: Symptoms of HAIs Caused by Gram-Negative Bacteria 49
Table 5: Risk Factors for Diagnosed Incident Cases of HAIs 52
Table 6: 7MM, Suspected Incident Cases of Select HAIs, Ages 18 Years, Both Sexes, N, Select Years 2016-2026 69
Table 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages 18 Years, Both Sexes, N, Select Years 2016-2026 70
Table 8: National and International Treatment Guidelines for HAIs 83
Table 9: HAI Disease Management, Country Profile - US 89
Table 10: HAI Disease Management, Region Profile - 5EU 91
Table 11: HAI Disease Management, Region Profile - Japan 92
Table 12: Common Susceptibility Patterns in Gram-Negative Bacteria Isolated From the General Hospital Setting (non-ICU) and ICUs 95
Table 13: Leading Branded Treatments for HAI, 2016 97
Table 14: SWOT Analysis of Main Antibiotic Classes for HAIs Caused by Gram-Negative Bacteria 98
Table 15: Product Profile - Avycaz 103
Table 16: Efficacy of Avycaz in Patients with cIAIs 104
Table 17: Efficacy of Avycaz in Patients with cUTIs 105
Table 18: Safety of Avycaz 106
Table 19: Product Profile - Zerbaxa 108
Table 20: Efficacy of Zerbaxa in Patients with cIAIs 109
Table 21: Efficacy of Zerbaxa in Patients with cUTIs 110
Table 22: Safety of Zerbaxa 111
Table 23: Product Profile - Piperacillin/tazobactam 113
Table 24: Efficacy of Piperacillin/tazobactam in Patients with cIAIs 114
Table 25: Efficacy of Piperacillin/tazobactam in Patients with HAP 115
Table 26: Efficacy of Piperacillin/tazobactam in Patients with cUTIs 115
Table 27: Safety of Piperacillin/Tazobactam 116
Table 28: Product Profile - Ticarcillin/clavulanate 117
Table 29: Efficacy of Ticarcillin/clavulanate in Patients with cIAIs1 118
Table 30: Product Profile - Aztreonam 120
Table 31: Efficacy of Aztreonam 121
Table 32: Safety of Aztreonam in Patients with Bacterial Infections 121
Table 33: Product Profile - Doribax 124
Table 34: Efficacy of Doribax in Patients with cIAIs 125
Table 35: Efficacy of Doribax in Patients with cUTIs 126
Table 36: Safety of Doribax 126
Table 37: Product Profile - Invanz 128
Table 38: Efficacy of Invanz in Patients with cIAIs 129
Table 39: Efficacy of Invanz in Patients with cUTIs 131
Table 40: Safety of Invanz 131
Table 41: Most Frequently Used Cephalosporins in HAIs 135
Table 42: Product Profile - Levofloxacin 137
Table 43: Efficacy of Levaquin in Patients with Nosocomial Pneumonia 138
Table 44: Efficacy of Levaquin in Patients with cUTIs and Acute Pyelonephritis 139
Table 45: Safety of Levofloxacin in Patients with Bacterial Infections 139
Table 46: Product Profile - Ciprofloxacin 141
Table 47: Efficacy of Ciprofloxacin in Patients with cUTIs 142
Table 48: Safety of Ciprofloxacin in Patients with Bacterial Infections 142
Table 49: Product Profile - Moxifloxacin 143
Table 50: Efficacy of Moxifloxacin in Patients with cIAIs 144
Table 51: Safety of Moxifloxacin in Patients with Bacterial Infections 145
Table 52: Aminoglycoside Susceptibility of Strains Isolated from Hospitalized Patients with Pneumonia* 150
Table 53: Product Profile - Amikacin 151
Table 54: Efficacy of Amikacin in Patients with Bacterial Infections 152
Table 55: Safety of Amikacin in Patients with Bacterial Infections 153
Table 56: Product Profile - Gentamicin 154
Table 57: Efficacy of Gentamicin in Patients with Bacterial Infections 155
Table 58: Safety of Gentamicin in Patients with Bacterial Infections 155
Table 59: Product Profile - Tobramycin 156
Table 60: Product Profile - Tygacil 158
Table 61: Efficacy of Tygacil in Patients with cIAIs 159
Table 62: Efficacy of Tygacil in Patients with HAP/VAP 160
Table 63: Safety of Tygacil 161
Table64: Infrequently Used Antibiotics for the Treatment of HAI Caused by Gram-Negative Bacteria 161
Table 65: Key Late-Stage Pipeline Agents for HAIs Caused by Gram-Negative Bacteria, 2017 190
Table 66: Product Profile - Avibactam/Aztreonam 192
Table 67: Pathogen Susceptibility to Avibactam/Aztreonam 193
Table 68: Avibactam/Aztreonam SWOT Analysis, 2017 195
Table 69: Product Profile - Meropenem/Vaborbactam 197
Table 70: Meropenem/Vaborbactam - Phase III Clinical Trials 199
Table 71: Meropenem/Vaborbactam SWOT Analysis, 2017 200
Table 72: Product Profile - Relebactam/Imipenem/Cilastin 202
Table 73: Relebactam/Imipenem/Cilastin - Phase II and Phase III Clinical Trials 204
Table 74: Relebactam/Imipenem/Cilastin - Phase II Results (cIAI/cUTI) 205
Table 75: Safety of Relebactam/Imipenem/Cilastin 206
Table 76: Relebactam/Imipenem/Cilastin SWOT Analysis, 2017 207
Table 77: Product Profile - Cefiderocol 209
Table 78: Cefiderocol - Phase II and Phase III Clinical Trials 210
Table 79: Cefiderocol SWOT Analysis, 2017 212
Table 80: Product Profile - Eravacycline 214
Table 81: Eravacycline - Phase II and Phase III Clinical Trials 216
Table 82: Eravacycline - Phase III Clinical Trials Results for cIAIs 217
Table 83: Eravacycline - Safety Profile 217
Table 84: Eravacycline SWOT Analysis, 2017 219
Table 85: Product Profile - Finafloxacin 221
Table 86: Finafloxacin - Phase II Efficacy for Patients with UTI 222
Table 87: Finafloxacin SWOT Analysis, 2017 223
Table 88: Product Profile - Plazomicin 226
Table 89: Plazomicin - Clinical Trials 227
Table 90: Plazomicin - Results from Phase III Trial with cUTI Patients 228
Table 91: Plazomicin - Results from Phase III Trial with cUTI Patients 228
Table 92: Plazomicin - Safety Results from Phase III Trials 229
Table 93: Eravacycline SWOT Analysis, 2017 230
Table 94: Product Profile - Panobacumab 232
Table 95: Aerumab - Phase II Clinical Trials 233
Table 96: Aerumab - Phase II Clinical Trial Results 233
Table 97: Aerumab SWOT Analysis, 2017 234
Table 98: Product Profile - MEDI3902 237
Table 99: MEDI3902 - Phase II Clinical Trials 237
Table 100: MEDI3902 - Safety Data 238
Table 101: MEDI3902 SWOT Analysis, 2017 239
Table 102: Drugs in Development for HAI Caused by Gram-Negative Bacteria, 2017 241
Table 103: Key Companies in the HAIs Marketplace in the 7MM, 2017 244
Table 104: Pfizers HAI Portfolio Assessment, 2017 248
Table 105: Merck& Cos Gram-Negative HAIs Portfolio Assessment, 2017 249
Table 106: The Medicines Companys Gram-Negative HAIs Portfolio Assessment, 2017 251
Table 107: Shionogis Gram-Negative HAIs Portfolio Assessment, 2017 252
Table 108: Tetraphase Pharmaceuticals Gram-Negative HAIs Portfolio Assessment, 2017 253
Table 109: MerLion Pharmaceuticals Gram-Negative HAIs Portfolio Assessment, 2017 254
Table 110: Achaogens Gram-Negative HAIs Portfolio Assessment, 2017 255
Table 111: Aridis HAI Portfolio Assessment, 2017 256
Table 112: MedImmunes Gram-Negative HAI Portfolio Assessment, 2017 258
Table 113: Allergans Gram-Negative HAI Portfolio Assessment, 2017 259
Table 114: Global (7MM) Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026 263
Table 115: HAIs Caused by Gram-Negative Bacteria - Global Drivers and Barriers, 2016-2026 267
Table 116: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026 269
Table 117: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the US, 2016-2026 272
Table 118: HAIs caused by Gram-Negative Bacteria - US Drivers and Barriers, 2016-2026 273
Table 119: 5EU Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, 2016-2026 275
Table 120: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in the 5EU, 2016-2026 278
Table 121: HAIs Caused by Gram-Negative Bacteria - 5EU Drivers and Barriers, 2016-2026 279
Table 122: Sales Forecasts ($M) for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026 281
Table 123: Key Events Impacting Sales for HAIs Caused by Gram-Negative Bacteria in Japan, 2016-2026 284
Table 124: HAIs Caused by Gram-Negative Bacteria - Japan Drivers and Barriers, 2016-2026 285
Table 125: Key Historical and Projected Launch Dates for HAI Caused by Gram-negative Bacteria Across the 7MM 341
Table 126: Projected Patent Expiry Dates for HAI Caused by Gram-negative Bacteria Across the 7MM 342
Table 127: Key Assumptions for Avycaz 344
Table 128: Key Assumptions for Zerbaxa 345
Table 129: Key Assumptions for Piperacillin/tazobactam 345
Table 130: Key Assumptions for Ticarcillin/tazobactam 346
Table 131: Key Assumptions for Aztreonam 347
Table 132: Key Assumptions for Doribax 348
Table 133: Key Assumptions for Invanz 348
Table 134: Key Assumptions for Meropenem 349
Table 135: Key Assumptions for Imipenem 349
Table 136: Key Assumptions for Cefoxitin 350
Table 137: Key Assumptions for Cefotaxime 351
Table 138: Key Assumptions for Ceftriaxone 352
Table 139: Key Assumptions for Cefoperazone 353
Table 140: Key Assumptions for Ceftazidime 354
Table 141: Key Assumptions for Cefepime 355
Table 142: Key Assumptions for Zevtera 356
Table 143: Key Assumptions for Levofloxacin 357
Table 144: Key Assumptions for Ciprofloxacin 358
Table 145: Key Assumptions for Moxifloxacin 359
Table 146: Key Assumptions for Amikacin 360
Table 147: Key Assumptions for Gentamicin 361
Table 148: Key Assumptions for Tobramycin 362
Table 149: Key Assumptions for Polymyxin B 363
Table 150: Key Assumptions for Polymyxin E 364
Table 151: Key Assumptions for Tygacil 365
Table 152: Key Assumptions for Other Antibiotics 366
Table 153: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 373

1.2 List of Figures
Figure 1: Global Sales for HAI Caused by Gram-Negative Bacteria by Region, 2016 and 2026 16
Figure 2: Company Portfolio Gap Analysis for HAIs against Gram-Negative Bacteria, 2016-2026 18
Figure 3: Competitive Assessment of the Late-Stage Pipeline for HAIs against Gram-Negative Bacteria 22
Figure 4: Illustration Depicting the Key Structural Properties of Gram-Negative Bacteria 29
Figure 5: Sites of Relevant Gram-Negative HAI Sites 37
Figure 6: Illustration Depicting the Key Mechanisms of Antibiotic Resistance Observed in Gram-Negative Bacteria 41
Figure 7: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site 57
Figure 8: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site 58
Figure 9: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent 59
Figure 10: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016 71
Figure 11: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages 18 Years, 2016 72
Figure 12: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages 18 Years, 2016 73
Figure 13: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages 18 Years, 2016 74
Figure 14: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages 18 Years, 2016 75
Figure 15: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages 18 Years, 2016 76
Figure 16: Empirical and Targeted Treatments of HAIs 85
Figure 17: Overview of the Unmet Needs for HAIs Caused by Gram-Negative Bacteria. 165
Figure 18: Overview of the Development Pipeline for HAI Against Gram-Negative Bacteria 187
Figure 19: HAIs Caused by Gram-Negative Bacteria - Phase IIIII Pipeline, 2017 188
Figure 20: Competitive Assessment of Late-Stage Pipeline Agents in HAIs Caused by Gram-Negative Bacteria, 2016-2026 189
Figure 21: Clinical and Commercial Positioning of Aztreonam/Avibactam 194
Figure 22: Clinical and Commercial Positioning of Meropenem/Vaborbactam 200
Figure 23: Clinical and Commercial Positioning of Relebactam/Imipenem/Cilastin 206
Figure 24: Clinical and Commercial Positioning of Cefiderocol 211
Figure 25: Clinical and Commercial Positioning of Eravacycline 218
Figure 26: Clinical and Commercial Positioning of Finafloxacin 223
Figure 27: Clinical and Commercial Positioning of Plazomicin 230
Figure 28: Clinical and Commercial Positioning of Aerumab 234
Figure 29: Clinical and Commercial Positioning of MEDI3902 239
Figure 30: Company Portfolio Gap Analysis in Gram-Negative HAIs, 2016-2026 245
Figure 31: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Country/Region, 2016 and 2026 265
Figure 32: Global Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria, by Drug Class, 2016 and 2026 266
Figure 33: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the US, by Drug Class, 2016 and 2026 271
Figure 34: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in the 5EU by Drug Class, 2016 and 2026 277
Figure 35: Sales for Therapeutics Against HAIs Caused by Gram-Negative Bacteria in Japan, by Drug Class, 2016 and 2026 283
Figure 36: Patient Flow Used for HAIs with Gram-Negative Bacteria 339

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *